Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.34 - $58.26
Previous CloseN/A
Volume45.38K
Average Volume (3M)420.54K
Market Cap
$2.50B
Enterprise Value$2.98B
Total Cash (Recent Filing)$39.51M
Total Debt (Recent Filing)$282.58K
Price to Earnings (P/E)―
Beta1.68
Next Earnings
May 08, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding63,282,726
10 Day Avg. Volume554,654
30 Day Avg. Volume420,536
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.01
Forecast
1Y Price Target
$77.00Price Target Upside111.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
MoonLake Immunotherapeutics News
PremiumCompany Announcements
MoonLake Immunotherapeutics Secures $500M Financing for Growth
PremiumCompany Announcements
MoonLake Immunotherapeutics Advances Clinical Trials in 2024
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSonelokimab has demonstrated a strong profile in a Phase IIb trial in psoriasis including a maximal response of 57% PASI 100, and a benign side effect profile.
Development PotentialBased on its differentiated profile, sonelokimab is expected to take meaningful share and create much shareholder value as it progresses through development.
Market PositionPovorcitinib's lukewarm Phase 3 results in HS are seen as a competition-clearing event for sonelokimab, likely leaving SLK in the pole position to emerge as the preferred advanced treatment option.
Bears Say
Financial PerformanceMoonLake recorded a full-year 2024 net loss of $1.89 per share, which is slightly higher than the forecasted net loss of $1.84 per share.
Research And Development CostsR&D expenses increased significantly year-over-year, mainly due to higher costs related to clinical trials with contract research organizations.
---
Ownership Overview
25.92% Insiders
15.86% Mutual Funds
0.13% Other Institutional Investors
57.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $36.34 and its highest was $58.26 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $2.50B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Feb 26, 2025. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.62 by -$0.1.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.76.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 63,282,726 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.62. Following the earnings report the stock price went up 4.027%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
---
MoonLake Immunotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.00 (111.83% Upside)
$77.00 (111.83% Upside)
Blogger Sentiment
Neutral
MLTX Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 71.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.20%
12-Months-Change
Fundamentals
Return on Equity
-25.24%
Trailing 12-Months
Asset Growth
-9.23%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
---
MLTX Stock 12 Month Forecast
Average Price Target
$77.00
▲(111.83% Upside)
Technical Analysis
AnaptysBio
―
Kiniksa Pharmaceuticals
―
RAPT Therapeutics
―
Immunovant
―
Beam Therapeutics
―
Best Analysts Covering MLTX
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+93.86%
reiterated a buy rating last month
Copying Thomas Smith's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +93.86% per trade.
---